Invitrolize secures seed funding from Expon Capital to expand the deployment of its innovative ALIsens® model for detecting respiratory sensitizers across Europe and the US.

Target Information

Invitrolize, a biotech startup based in Belvaux, Luxembourg, has recently secured seed funding from Expon Capital’s Digital Tech Fund and individual investors. The primary focus of the funding is to facilitate the global deployment of ALIsens®, the first in vitro model specifically designed to identify respiratory sensitizers under realistic exposure conditions. This innovative model promises scalability, reproducibility, stability, and cost-effectiveness, establishing itself as a potential standard for regulatory use in various industries.

ALIsens® addresses a significant challenge in toxicology by providing an ethical and regulatory-compliant method for the early detection of respiratory sensitizers, thereby eliminating the need for animal testing. This groundbreaking solution empowers research and development teams across multiple sectors, including pharmaceutical, cosmetic, chemical, and consumer goods, contributing to a new paradigm in chemical safety.

Industry Overview

The demand for safe and effective chemical testing methods is swiftly increasing, particularly in Europe and the United States, where regulatory frameworks are becoming more stringent. Inhalable chemical compounds used in everyday products, such as personal care items,